Sakae Asanuma

President and CEO
Astellas Venture Management LLC

Sakae Asanuma, CFA, MBA is President & CEO at Astellas Venture Management and US Head of Astellas Innovation Management. Sakae is a Bay area based Venture Capitalist, focusing on Biotech Investments since 2000. He has invested in 30+ life science start-ups, achieving 7 IPOs and 10 M&As to date

Sakae joined Astellas Venture Management (AVM) in June 2011 and has been running AVM/AIM-US since 2012. Prior to AVM, he was CEO at Yasuda Enterprise Development America (Japan’s major VC firm with $800M under management) from 2000 to 2011, originating all of the US biotech investment activities for Yasuda and supporting business development discussions with Japanese pharmaceutical companies on behalf of his portfolios.

Prior to Yasuda, Venture Capitalist and Buy-side Equity Analyst in Japan at Meiji-Yasuda Life Insurance Company from 1988 to 1999, managing its $20B equity portfolios. Sakae holds a Master of Business Administration from Carnegie Mellon University.

Check out the incredible speaker line-up to see who will be joining Sakae.

Download The Latest Agenda

Day 2

Sunday, April 10th, 2016

10:10 PANEL: Innovative Financing And Deal Structures

•Exploring the current state of big pharma partnering—what are the recent trends?

•Examining option-based M&A deals—a win/win for investors and buyers?

•Discovering more innovative deal types and new ways to structure equity investments